A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
2,800
Pfizer Investigational Site
Fosterhill, Aberdeen, United Kingdom
Pfizer Investigational Site
Irvine, Ayrshire, United Kingdom
Pfizer Investigational Site
Midsomer Norton, Bath, United Kingdom
Pfizer Investigational Site
Reading, Berkshire, United Kingdom
Pfizer Investigational Site
Slough, Berkshire, United Kingdom
Time from randomization to the occurrence of a primary clinical endpoint
i.e. major coronary event or CABG or other coronary revascularization procedure
or unstable angina or resuscitated cardiac arrest or stroke.
The incidence rate of a primary clinical and endpoint; the time from randomization
to the occurrence of and the incidence rate of other parameters e.g. total
mortality, any cardiovascular event, new PVD etc. and the percent change from
baseline in various lipid and lipoprotein parameters.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Maidenhead, Berskhire, United Kingdom
Pfizer Investigational Site
Edgbaston, Birmingham, United Kingdom
Pfizer Investigational Site
Frenchay, Bristol, United Kingdom
Pfizer Investigational Site
Llanishen, Cardiff, United Kingdom
Pfizer Investigational Site
Wrexham, Clwydd, United Kingdom
...and 125 more locations